메뉴 건너뛰기




Volumn 92, Issue 11, 2003, Pages 1287-1293

Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN;

EID: 0242544064     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.08.009     Document Type: Article
Times cited : (103)

References (19)
  • 1
    • 0035451307 scopus 로고    scopus 로고
    • Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
    • Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 88:2001;504-508.
    • (2001) Am J Cardiol , vol.88 , pp. 504-508
    • Olsson, A.G.1    Pears, J.2    Mckellar, J.3    Mizan, J.4    Raza, A.5
  • 3
    • 0015348189 scopus 로고
    • Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
    • Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
    • (1972) Clin Chem , vol.18 , pp. 499-502
    • Friedewald, W.T.1    Levy, R.I.2    Frederickson, D.S.3
  • 5
    • 0024549783 scopus 로고
    • The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements
    • Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program an approach to accurate and precise lipid measurements . Clin Lab Med. 9:1989;105-135.
    • (1989) Clin Lab Med , vol.9 , pp. 105-135
    • Myers, G.L.1    Cooper, G.R.2    Winn, C.L.3    Smith, S.J.4
  • 6
    • 0001742423 scopus 로고
    • Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology
    • (abstr)
    • Steiner P.M., Freidel J., Bremmer W., Stein E.A. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology. (abstr) J Clin Chem Clin Biochem. 19:1981;850.
    • (1981) J Clin Chem Clin Biochem , vol.19 , pp. 850
    • Steiner, P.M.1    Freidel, J.2    Bremmer, W.3    Stein, E.A.4
  • 7
    • 0017811544 scopus 로고
    • A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol
    • Warnick G., Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76.
    • (1978) J Lipid Res , vol.19 , pp. 65-76
    • Warnick, G.1    Albers, J.2
  • 8
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    • Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 10
    • 0030972796 scopus 로고    scopus 로고
    • The rule of 5 and the rule of 7 in lipid lowering by statin drugs
    • Roberts W.C. The rule of 5 and the rule of 7 in lipid lowering by statin drugs. Am J Cardiol. 80:1997;106-107.
    • (1997) Am J Cardiol , vol.80 , pp. 106-107
    • Roberts, W.C.1
  • 11
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
    • Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 92:2003;152-160.
    • (2003) Am J Cardiol , vol.92 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3    Bays, H.E.4    Mckenney, J.M.5    Miller, E.6    Cain, V.A.7    Blasetto, J.W.8
  • 12
    • 0032032592 scopus 로고    scopus 로고
    • Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
    • Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol. 81:1998;582-587.
    • (1998) Am J Cardiol , vol.81 , pp. 582-587
    • Jones, P.1    Kafonek, S.2    Laurora, I.3    Hunninghake, D.4
  • 13
    • 0033562756 scopus 로고    scopus 로고
    • Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
    • Crouse J.R., Frohlich J., Ose L., Mercuri M., Tobert J.A. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 83:1999;1476-1477.
    • (1999) Am J Cardiol , vol.83 , pp. 1476-1477
    • Crouse, J.R.1    Frohlich, J.2    Ose, L.3    Mercuri, M.4    Tobert, J.A.5
  • 14
    • 0035941786 scopus 로고    scopus 로고
    • Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
    • Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) a prospective, randomised, double-blind trial . Lancet. 357:2001;577-581.
    • (2001) Lancet , vol.357 , pp. 577-581
    • Smilde, T.J.1    Van Wissen, S.2    Wollersheim, H.3    Trip, M.D.4    Kastelein, J.J.5    Stalenhoef, A.F.6
  • 15
    • 0032169240 scopus 로고    scopus 로고
    • Inflammation, pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol levels
    • Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
    • (1998) Circulation , vol.98 , pp. 839-844
    • Ridker, P.M.1    Rifai, N.2    Pfeffer, M.A.3    Sacks, F.M.4    Moye, L.A.5    Goldman, S.6    Flaker, G.C.7    Braunwald, E.8
  • 16
    • 0035963529 scopus 로고    scopus 로고
    • Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events
    • Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto A.M. Jr. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
    • (2001) N Engl J Med , vol.344 , pp. 1959-1965
    • Ridker, P.M.1    Rifai, N.2    Clearfield, M.3    Downs, J.R.4    Weis, S.E.5    Miles, J.S.6    Gotto Jr., A.M.7
  • 17
    • 0034074546 scopus 로고    scopus 로고
    • The role of inflammation in cardiovascular disease
    • (editorial)
    • Kuller L.W., Tracy R.P. The role of inflammation in cardiovascular disease. (editorial) Arterioscler Thromb Vasc Biol. 20:2000;901.
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 901
    • Kuller, L.W.1    Tracy, R.P.2
  • 19
    • 84872291610 scopus 로고    scopus 로고
    • July 9, 2003. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Accessed August 4, 2003
    • Endocrinologic and Metabolic Drugs Advisory Committee (transcript). July 9, 2003. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.pdf. Accessed August 4, 2003.
    • Endocrinologic and Metabolic Drugs Advisory Committee (transcript)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.